FLT3 and acute graft versus host disease: This real-world study aimed to address this knowledge gap in an Asian cohort.<h4>Method and result</h4>Patients with FLT3-mutated R/R AML received gilteritinib before transplantation, and those achieving engraftment without grade ≥ 2 acute graft-versus-host disease were offered posttransplant maintenance between days 30 and 90.